Literature DB >> 12050349

Rituximab plus CHOP for diffuse large-B-cell lymphoma.

Saad Akhtar, Irfan Maghfoor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050349     DOI: 10.1056/NEJM200206063462317

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.

Authors:  Dong Won Baek; Hee Jeong Cho; Ju-Hyung Kim; Sang Kyun Sohn; Ga-Young Song; Seo-Yeon Ahn; Sung-Hoon Jung; Jae Sook Ahn; Je-Jung Lee; Hyeoung-Joon Kim; Shin-Young Jeong; Chae Moon Hong; Jung-Joon Min; Joon-Ho Moon; Deok-Hwan Yang
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 3.  New agents in the treatment of childhood leukemias and myelodysplastic syndromes.

Authors:  Seth J Corey
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

4.  Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.

Authors:  Kazumi Hayashi; Eijiro Nagasaki; Shin Kan; Masaki Ito; Yuko Kamata; Sadamu Homma; Keisuke Aiba
Journal:  Cancer Sci       Date:  2016-04-07       Impact factor: 6.716

5.  Trial Watch: Toll-like receptor agonists in oncological indications.

Authors:  Fernando Aranda; Erika Vacchelli; Florine Obrist; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Isabelle Cremer; Jan Henrik Ter Meulen; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-08-01       Impact factor: 8.110

6.  Trial watch: Immunostimulatory cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-03       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.